Diagnostic value of determination of galectin-3 - the new biomarker of the chronic heart failure

Cover Page

Cite item

Full Text

Abstract

The reviewsummarizes the results of clinical trials in which galectin-3 was assessed as biomarker of heart failure. In addition, most relevant information on galectin-3 received in in vitro and in vivo research is given with respect of heart failure.

About the authors

K. A Gyamdzhyan

Department of Clinical Pharmacology and Internal Propaedeutic Medicine, Sechenov first medical university

аспирант каф. клинической фармакологии и пропедевтики внутренних болезней

M. L Maksimov

Department of Clinical Pharmacology and Internal Propaedeutic Medicine, Sechenov first medical university

д-р мед. наук, проф. каф. клинической фармакологии и пропедевтики внутренних болезней

References

  1. Агеев Ф.Т., Арутюнов Г.П. Хроническая сердечная недостаточность. М.: ГЭОТАР-Медиа, 2010.
  2. Ho J.M et al. Galectin-3, a marker of cardiac fibrosis, predicts incidence heart failure in the community. JACC 2012; 60 (14):1249-56.
  3. Максимов М.Л. Влияние кардиоселективного бета - блокатора небиволола на глобальную и локальную сократимость миокарда у больных ишемической болезнью сердца, осложненной хронической сердечной недостаточностью. Автореф. дис. ... канд. мед. наук. М., 2004.
  4. Агеев Ф.Т., Азизова А.Г. Галектин-3 - новый биохимический маркер сердечной недостаточности. Журн. Сердечная недостаточность. 2011; 12 (2).
  5. Драпкина О.М., Дуболазова Ю.В. Применение биологических маркеров в диагностике диастолической сердечной недостаточности. Журн. Сердечная недостаточность. 2011; 12 (6).
  6. Kramer F. Galectin-3: clinical utility and prognostic value in patients with heart failure. Reas Rep Clin Cardiology 2013; 4: 13-2.
  7. Kim H, Lee J et al. Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell Biol Int 2007; 31 (7): 655-2.
  8. Ochieng J et al. Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Biochem Biophys Res Commun 1998: 246 (3): 788-91.
  9. Karlsson A et al. Galectin-3 functions as an opsonin and enhances the macrophage clearance of apoptotic neutrophils. Glycobiology 2009; 19 (1): 16-20.
  10. Sharma U.C et al. Galectin-3 marks activated macrophages in failure - prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004; 110 (19): 3121-8.
  11. Shroen B, Heymans S et al. Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure - prone cardiac hypertrophy. Circ Res 2004; 95 (5): 515-22.
  12. Henderson N.C et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 2006; 103 (13): 5060-5.
  13. Liu Y.H et al. N-acetyl - seryl - aspartyl - lysyl - proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth - regulatory lectin. Am J Physiol Heart Circ Physiol 2009; 296 (2): H404-H412.
  14. Calvier L et al. Galectin-3 mediates aldosterone - induced vascular fibrosis. Atheroscler Thromb Vasc Biol 2013; 33 (1): 67-75.
  15. de Boer R.A et al. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep 2010; 7 (1): 1-8.
  16. van Kimmenade R.R et al. Utility of aminoterminal pro - brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006; 48 (6): 1217-24.
  17. Дуболазова Ю.В. Оценка клинического течения хронической сердечной недостаточности с сохраненной фракцией выброса. Автореф. дис. ... канд. мед. наук. М., 2012.
  18. Gullestad L et al. CORONA Study group. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J 2012; 33 (18): 2290-6.
  19. Kjekhus J et al. CORONA group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357 (22): 2248-61.
  20. Cohn J.N et al. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin - receptor blocker valsartan in chronic heart failure. N Eng J Med 2001; 345 (23): 1667-75.
  21. Anand I.S et al. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the ValHeFT. Eur J of Heart Failure Epub 2013, Jan 4.
  22. Milting H et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant 2008; 27 (6): 589-96.
  23. Erkilet G et al. Plasma galectin-3 is increased in terminal heart failure patients and is elevated in patients surviving mechanical circulatory support. J Heart Lung Transplant 2010; 29 (2): S65.
  24. Lopez-Andrez N et al. Association of galectin-3 and fibrosis markers with long - term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction and dyssynchrony: insights from CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 2012; 14 (1).
  25. Lok D.J et al. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol. Epub August 12, 2012
  26. Felker G.M et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail 2012; 5 (1): 72-8.
  27. Lok D.J et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from DEAL-HF study. Clin Res Cardiol 2010; 99 (5): 323-28.
  28. Erkilet G et al. The biomarker plasma galectin-3 in advanced heart failure and survival with mechanical circulatory support devices. J Heart Lung Transplant 2013; 32 (2): 221-30.
  29. de Boer R.A et al. Predictive values of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011; 43 (1): 60-8.
  30. Shah R.V et al. Galectin-3, cardiac structure and function and long - term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010; 12 (8): 826-32.
  31. de Boer R.A et al. The fibrosis marker galectin-3 and outcome in general population. J Intern Med 2012; 272 (1): 55-64.
  32. Biomarker Definitions Working Group. Biomarkers and surrogate end - points: preffered definitions and conceptual framework. Clin Pharmacol Ther 2001; 69 (3): 89-95.

Copyright (c) 2014 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies